产后循环microRNA提升既往妊娠期糖尿病女性未来2型糖尿病预测
该观察性研究在103名妊娠期糖尿病(GDM)女性产后12周采集血浆,用TaqMan实时PCR检测754种microRNA并结合机器学习筛选标志物。验证集中miR-369-3p在进展者与非进展者间仍有显著差异(p<0.05);在含6项传统危险因素的临床模型中加入产后12周miR-369-3p后,预测未来2型糖尿病的AUC由0.83(95%CI 0.68,0.97)提升至0.92(95%CI 0.84,1.00)。
要点
- 产后12周血浆miR-369-3p在验证集中与未来2型糖尿病进展显著相关(p<0.05)。
- 在6项传统危险因素模型中加入miR-369-3p,AUC由0.83升至0.92。
- 这是首次在既往GDM女性中展示基于miRNA的2型糖尿病预测。
核心结论
- 在既往GDM女性中,产后12周循环miR-369-3p可提升未来2型糖尿病的预测效能。
- 该研究首次展示基于miRNA的2型糖尿病预测,有助于早期生活方式或药物干预以预防2型糖尿病。
研究设计与样本
- 观察性研究,103名GDM妊娠后女性于产后12周采集血浆样本。
- 发现阶段用TaqMan实时PCR在OpenArray平台检测754种miRNA,比较2型糖尿病非进展者(n=11)与进展者(n=10)。
- 采用惩罚逻辑回归结合bootstrapping的机器学习算法筛选miRNA。
- 验证样本集n=82(非进展者71例,进展者11例),校正年龄及多重比较。
主要发现
- 验证集中miR-369-3p水平在进展者与非进展者间仍显著不同(p<0.05)。
- 含6项传统危险因素(年龄、BMI、孕期空腹血糖、产后空腹血糖、胆固醇、甘油三酯)的临床模型AUC为0.83(95%CI 0.68,0.97)。
- 加入产后12周循环miR-369-3p后,预测未来2型糖尿病的AUC提升至0.92(95%CI 0.84,1.00)。
关键数值与推荐
- 验证集中miR-369-3p在进展者与非进展者间差异显著(p<0.05),校正年龄并校正多重比较。
- 传统临床模型(6项危险因素)预测2型糖尿病AUC 0.83(95%CI 0.68,0.97)。
- 传统模型加miR-369-3p后AUC 0.92(95%CI 0.84,1.00)。
临床怎么用
- 对既往GDM女性,可在产后12周检测循环miR-369-3p以辅助未来2型糖尿病风险分层。
- 将miR-369-3p加入含年龄、BMI、孕期及产后空腹血糖、胆固醇、甘油三酯的传统模型可改善预测。
- 预测效能提升有助于识别高风险者并尽早启动生活方式或药物干预以预防2型糖尿病。
局限性
- 发现队列样本量小(非进展者n=11,进展者n=10)。
- 验证集进展者仅11例,事件数有限。
- 研究为观察性设计,miRNA检测方法与平台限于TaqMan实时PCR OpenArray。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Type 2 diabetes mellitus is a major cause of morbidity and death worldwide. Women with gestational diabetes mellitus (GDM) have greater than a sevenfold higher risk of developing type 2 diabetes in later life. Accurate methods for postpartum type 2 diabetes risk stratification are lacking. Circulating microRNAs (miRNAs) are well recognised as biomarkers/mediators of metabolic disease. We aimed to determine whether postpartum circulating miRNAs can predict the development of type 2 diabetes in women with previous GDM. METHODS: In an observational study, plasma samples were collected at 12 weeks postpartum from 103 women following GDM pregnancy. Utilising a discovery approach, we measured 754 miRNAs in plasma from type 2 diabetes non-progressors (n = 11) and type 2 diabetes progressors (n = 10) using TaqMan-based real-time PCR on an OpenArray platform. Machine learning algorithms involving penalised logistic regression followed by bootstrapping were implemented. RESULTS: Fifteen miRNAs were selected based on their importance in discriminating type 2 diabetes progressors from non-progressors in our discovery cohort. The levels of miRNA miR-369-3p remained significantly different (p < 0.05) between progressors and non-progressors in the validation sample set (n = 82; 71 non-progressors, 11 progressors) after adjusting for age and correcting for multiple comparisons. In a clinical model of prediction of type 2 diabetes that included six traditional risk factors (age, BMI, pregnancy fasting glucose, postpartum fasting glucose, cholesterol and triacylglycerols), the addition of the circulating miR-369-3p measured at 12 weeks postpartum improved the prediction of future type 2 diabetes from traditional AUC 0.83 (95% CI 0.68, 0.97) to an AUC 0.92 (95% CI 0.84, 1.00). CONCLUSIONS: This is the first demonstration of miRNA-based type 2 diabetes prediction in women with previous GDM. Improved prediction will facilitate early lifestyle/drug intervention for type 2 diabetes prevention.
引用
- Joglekar MV, Wong WKM, Ema FK, et al. Postpartum circulating microRNA enhances prediction of future type 2 diabetes in women with previous gestational diabetes. Diabetologia. 2021. PMID: 33755745. doi:10.1007/s00125-021-05429-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。